KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Other Non Operating Income (2016 - 2025)

Arbutus Biopharma's Other Non Operating Income history spans 13 years, with the latest figure at -$12000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 340.0% year-over-year to -$12000.0; the TTM value through Sep 2025 reached -$20000.0, down 900.0%, while the annual FY2024 figure was -$49000.0, 296.0% down from the prior year.
  • Other Non Operating Income for Q3 2025 was -$12000.0 at Arbutus Biopharma, down from $21000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $28000.0 in Q1 2021 and bottomed at -$33000.0 in Q4 2024.
  • The 5-year median for Other Non Operating Income is $2000.0 (2022), against an average of -$1555.6.
  • The largest annual shift saw Other Non Operating Income skyrocketed 450.0% in 2023 before it plummeted 900.0% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $5000.0 in 2021, then tumbled by 180.0% to -$4000.0 in 2022, then surged by 450.0% to $14000.0 in 2023, then crashed by 335.71% to -$33000.0 in 2024, then soared by 63.64% to -$12000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Other Non Operating Income are -$12000.0 (Q3 2025), $21000.0 (Q2 2025), and $4000.0 (Q1 2025).